Show simple item record

dc.contributor.authorLockman, Shahin
dc.contributor.authorHughes, Michael David
dc.contributor.authorSawe, Fred
dc.contributor.authorZheng, Yu
dc.contributor.authorMcIntyre, James
dc.contributor.authorChipato, Tsungai
dc.contributor.authorAsmelash, Aida
dc.contributor.authorRassool, Mohammed
dc.contributor.authorKimaiyo, Sylvester
dc.contributor.authorShaffer, Douglas
dc.contributor.authorHosseinipour, Mina
dc.contributor.authorMohapi, Lerato
dc.contributor.authorSsali, Francis
dc.contributor.authorChibowa, Margret
dc.contributor.authorAmod, Farida
dc.contributor.authorHalvas, Elias
dc.contributor.authorHogg, Evelyn
dc.contributor.authorAlston-Smith, Beverly
dc.contributor.authorSmith, Laura
dc.contributor.authorSchooley, Robert
dc.contributor.authorMellors, John
dc.contributor.authorCurrier, Judith
dc.date.accessioned2013-04-03T19:40:29Z
dc.date.issued2012
dc.identifier.citationLockman, Shahin, Michael Hughes, Fred Sawe, Yu Zheng, James McIntyre, Tsungai Chipato, Aida Asmelash, et al. 2012. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Medicine 9(6): e1001236.en_US
dc.identifier.issn1549-1277en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10497280
dc.description.abstractBackground: Nevirapine (NVP) is widely used in antiretroviral treatment (ART) of HIV-1 globally. The primary objective of the AA5208/OCTANE trial was to compare the efficacy of NVP-based versus lopinavir/ritonavir (LPV/r)-based initial ART. Methods and Findings: In seven African countries (Botswana, Kenya, Malawi, South Africa, Uganda, Zambia, and Zimbabwe), 500 antiretroviral-naïve HIV-infected women with CD4<200 cells/\(mm^3\) were enrolled into a two-arm randomized trial to initiate open-label ART with tenofovir (TDF)/emtricitabine (FTC) once/day plus either NVP (n = 249) or LPV/r (n = 251) twice/day, and followed for ≥48 weeks. The primary endpoint was time from randomization to death or confirmed virologic failure ([VF]) (plasma HIV RNA<1 \(log_{10}\) below baseline 12 weeks after treatment initiation, or ≥400 copies/ml at or after 24 weeks), with comparison between treatments based on hazard ratios (HRs) in intention-to-treat analysis. Equivalence of randomized treatments was defined as finding the 95% CI for HR for virological failure or death in the range 0.5 to 2.0. Baseline characteristics were (median): age = 34 years, CD4 = 121 cells/\(mm^3\), HIV RNA = 5.2 \(log_{10}\) copies/ml. Median follow-up = 118 weeks; 29 (6%) women were lost to follow-up. 42 women (37 VFs, five deaths; 17%) in the NVP and 50 (43 VFs, seven deaths; 20%) in the LPV/r arm reached the primary endpoint (HR 0.85, 95% CI 0.56–1.29). During initial assigned treatment, 14% and 16% of women receiving NVP and LPV/r experienced grade 3/4 signs/symptoms and 26% and 22% experienced grade 3/4 laboratory abnormalities. However, 35 (14%) women discontinued NVP because of adverse events, most in the first 8 weeks, versus none for LPV/r (p<0.001). VF, death, or permanent treatment discontinuation occurred in 80 (32%) of NVP and 54 (22%) of LPV/r arms (HR = 1.7, 95% CI 1.2–2.4), with the difference primarily due to more treatment discontinuation in the NVP arm. 13 (45%) of 29 women tested in the NVP versus six (15%) of 40 in the LPV/r arm had any drug resistance mutation at time of VF. Conclusions: Initial ART with NVP+TDF/FTC demonstrated equivalent virologic efficacy but higher rates of treatment discontinuation and new drug resistance compared with LPV/r+TDF/FTC in antiretroviral-naïve women with CD4<200 cells/\(mm^3\).en_US
dc.language.isoen_USen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.isversionofdoi:10.1371/journal.pmed.1001236en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373629/pdf/en_US
dash.licenseLAA
dc.subjectMedicineen_US
dc.subjectGlobal Healthen_US
dc.subjectInfectious Diseasesen_US
dc.subjectViral Diseasesen_US
dc.subjectHIVen_US
dc.subjectHIV diagnosis and managementen_US
dc.titleNevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trialen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalPLoS Medicineen_US
dash.depositing.authorLockman, Shahin
dc.date.available2013-04-03T19:40:29Z
dc.identifier.doi10.1371/journal.pmed.1001236*
dash.authorsorderedfalse
dash.contributor.affiliatedZheng, Yu
dash.contributor.affiliatedHughes, Michael
dash.contributor.affiliatedLockman, Shahin


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record